ISCT22: RoosterBio, ShiftBio partner to harness the power of MSCs, exosomes

May 10, 2022

RoosterBio, a supplier of human mesenchymal stem/stromal cells (MSCs), recently announced a strategic partnership with ShiftBio, a South Korean company that specializes in exosome technology.

Tim Kelly, PhD, CEO of RoosterBio, told at the International Society for Cell & Gene Therapy (ISCT) 2022 annual meeting in San Francisco that ShiftBio will leverage RoosterBio's cell and media product portfolio as part of the collaboration.

"There's just a tremendous amount of interest and excitement about the potential of exosome therapies," Kelly said. "We believe that MSCs are really the optimal cellular source for exosomes, because you're getting all the therapeutic benefits of the MSC contained within that extracellular vesicle."

MSCs release lipid-bound extracellular vesicles, a broad category of tiny nano-sized particles including exosomes that mediate cell-to-cell communication, tissue homeostasis, and physiology.

Kelly also said that the industry is "anxiously awaiting" the U.S. Food and Drug Administration's approval of the first MSC-based therapy, which could happen within the next year.

Watch the video below to learn more.

ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with at the International Society for Cell & Gene Therapy (ISCT)...
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis,...
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes...
ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic...
ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...
ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with
ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...

Copyright © 2022

Last Updated 7/20/2022 2:15:48 PM